Cited 702 times in
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.